I work in cancer research and have seen immune-based therpaies evolve. These therapies are all the rage (evidenced by opdivo and keytruda commercials for luncg cancer on nightly news). I believe this too be a bubble and there is good reason to think the field is saturated and many companies are chasing (this would include major pharma Roche, Genentech, AstraZeneca and a host of smaller biotech) diminishing clinical benefits. If I wanted to short the whole field, what would be a good strategy? I am relatively comforatable with typical investments, but not so much with shorts/puts/margins, etc. Suggestions?
Submitted June 07, 2018 at 12:05PM by msmith83 https://ift.tt/2Joh9Pg
